Stock SUPN SUPERNUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Supernus Pharmaceuticals, Inc.

Equities

SUPN

US8684591089

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-09-18 EDT 		5-day change 1st Jan Change
31.84 USD +0.38% Intraday chart for Supernus Pharmaceuticals, Inc. +2.45% +10.02%
09-04 Transcript : Supernus Pharmaceuticals, Inc. Presents at Wells Fargo 2024 Healthcare Conference, Sep-04-2024 04:30 PM
08-19 Sector Update: Health Care Stocks Edge Higher Premarket Monday MT

Press Releases

Search
See the results
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
100% Free Registration
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
GL
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
GL
Supernus: Q2 Earnings Snapshot
AQ
Supernus Announces Second Quarter 2024 Financial Results
GL
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
GL
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
AQ
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
GL
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
GL
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
GL
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
PR
Supernus Pharmaceuticals : 817P202 Interim Data Presentation May 2024 Final
PU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
PR
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
GL
Supernus Announces First Quarter 2024 Financial Results
GL
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
PR
Supernus Pharmaceuticals : 2023 Annual Report
PU
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
BU
Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
BU
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
GL
The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SUPN Stock
  4. News Supernus Pharmaceuticals, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition